VERZENIO

Peak

abemaciclib

NDAORALTABLETPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
116

Mechanism of Action

Kinase Inhibitors

Pharmacologic Class:

Kinase Inhibitor

Clinical Trials (5)

NCT07174336Phase 3Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Started Dec 2025
920 enrolled
Breast NeoplasmsNeoplasm Metastasis
NCT07100106Phase 1/2Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Started Oct 2025
285 enrolled
Breast Cancer
NCT06630325Phase 2Active Not Recruiting

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Started Jun 2025
30 enrolled
Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma+11 more
NCT06810544Phase 1/2Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Started Mar 2025
191 enrolled
Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4 more
NCT05940493Phase 2Recruiting

Abemaciclib in Newly Diagnosed Meningioma Patients

Started Mar 2025
72 enrolled
Meningioma

Loss of Exclusivity

LOE Date
Sep 28, 2031
67 months away
Patent Expiry
Sep 28, 2031

Patent Records (1)

Patent #ExpiryTypeUse Code
7855211
Sep 28, 2031
SubstanceProduct
U-3242